January 5, 2009 ITSI Biosciences is a subrecipient of a 5 year $2 million RO1 grant to study prostate cancer

ITSI Bioscience has announced that it is a Subrecipient of a $2 million 5 year RO1 grant awarded to Dr Karam El-Bayoumy of Penn State University Cancer Center. This NCI subaward will fund proteomics research at ITSI Biosciences, focusing on the identification of biomarkers of prostate cancer risk. Specifically, ITSIBio will utilize high performance 2D-DIGE MS and nano-LC/MS/MS to identify and characterize redox-sensitive proteins, and global proteomic patterns associated with the form and dose of selenium administered to human subjects, and those associated with the age of the subjects.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *